Rhumbline Advisers Purchases 8,797 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Rhumbline Advisers grew its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 5.3% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 175,335 shares of the company’s stock after buying an additional 8,797 shares during the quarter. Rhumbline Advisers owned approximately 0.18% of Intellia Therapeutics worth $3,924,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. raised its position in shares of Intellia Therapeutics by 2.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 700,228 shares of the company’s stock worth $21,350,000 after acquiring an additional 18,987 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Intellia Therapeutics by 5.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,170,829 shares of the company’s stock valued at $35,704,000 after buying an additional 60,748 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its position in shares of Intellia Therapeutics by 23.3% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 8,204 shares of the company’s stock worth $242,000 after purchasing an additional 1,553 shares during the period. Vanguard Personalized Indexing Management LLC bought a new position in shares of Intellia Therapeutics during the 4th quarter valued at about $206,000. Finally, Norges Bank acquired a new position in shares of Intellia Therapeutics in the fourth quarter valued at approximately $16,348,000. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Stock Down 2.5 %

NTLA stock opened at $21.51 on Tuesday. The business has a 50-day simple moving average of $23.38 and a 200 day simple moving average of $24.33. The company has a market cap of $2.18 billion, a PE ratio of -4.01 and a beta of 1.77. Intellia Therapeutics, Inc. has a 52 week low of $19.21 and a 52 week high of $35.88.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($1.52) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.29). The company had revenue of $7.00 million during the quarter, compared to analyst estimates of $19.68 million. The firm’s revenue was down 48.5% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.40) EPS. On average, analysts anticipate that Intellia Therapeutics, Inc. will post -5.19 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. StockNews.com upgraded Intellia Therapeutics to a “sell” rating in a report on Thursday, June 27th. Stifel Nicolaus lowered their price target on Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating on the stock in a research report on Wednesday, September 11th. Evercore ISI raised shares of Intellia Therapeutics to a “strong-buy” rating in a research note on Friday, August 9th. Canaccord Genuity Group reiterated a “buy” rating and set a $73.00 price target on shares of Intellia Therapeutics in a report on Thursday, June 27th. Finally, JPMorgan Chase & Co. reduced their target price on Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating for the company in a research note on Monday, August 12th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Intellia Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $61.77.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.